Peripheral Arterial Occlusive Disease (PAOD)

Background Information

Peripheral arterial occlusive disease is a chronic vascular disease of the arteries, affecting the arteries of the lower limb. In the progression of the disease, the arteries supplying the extremities, or more rarely the main artery (aorta), are narrowing (stenosis) or closing (occlusion). The constriction of blood vessels leads to a blood flow reduction and hence to a limited oxygen supply. Thereby the extremities, in most cases the lower ones, are in a situation of either acute or chronic ischaemia. The lack of blood supply leads to numbness, pain, and dangerous infections in developing ulcers (“Peripheral Arterial Disease”, Merck Manual of Diagnosis and Therapy Professional Edition, 2010).

ABCB5-positive (ABCB5+) cells were recently shown to play a significant role in angiogenesis and neo-vascularization in several animal models and the administration of ABCB5+ cells in acute and chronic cutaneous wound healing models results in enhanced wound healing.

Mesenchymal stem cells (MSCs) have been studied and used for more than a decade now to treat various diseases (Casiraghi et al., 2013). MSCs are multipotent cells that can replicate as undifferentiated cells and that have the potential to differentiate into adipocytic, chondrocytic, or osteocytic lineages (Pittenger et al., 1999).

The examinations of the laboratory of Prof. Dr. Frank lead to the identification of a distinct subpopulation of ABCB5+ progenitor cells isolated from human skin. To isolate those cells, a specific and sensitive antibody was created (Frank, et al., 2003) and purified under GMP-conditions as well as tested for viral contaminations (TICEBA).

TICEBA GmbH has developed a highly-standardized process to expand and accumulate allogeneic ABCB5+ mesenchymal stem cells from human donor skin samples and to isolate these stem cells using a bead-coupled highly specific monoclonal antibody.

Allogeneic ABCB5+ mesenchymal stem cells are intended for the treatment of PAOD by triggering angiogenesis in the affected limb and improve the blood perfusion. After the perfusion is restored, the wound healing is expected to proceed normally.


You will find informationen on the allogeneic clinical trial with ABCB+ mesenchymal stem cells HERE.



« back

Clinical Trials

We are now also recruiting patients for further clinical studies in phase I/IIa with allogeneic ABCB5-positive (ABCB5+) mesenchymal stem cells for the following indications: chronic venous ulcers (CVU), diabetic foot ulcers (DFU) and peripheral arterial occlusive disease (PAOD). For more information click HERE.


Besides the authorization to manufacture a human medicinal product in accordance with § 13 (1) of the German Medicinal Products Act (AMG) for autologous mesenchymal stem cells, TICEBA is also authorized to manufacture a medicinal product for allogeneic mesenchymal as well as allogeneic limbal ABCB5 + stem cells following a recent extension. For more information click HERE.

The Story of Stem Cells

Review our category "The Story of Stem Cells" with the newest topic "Stem cells in wound healing" HERE.